Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone…

Read MoreStudy Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry IRLCA und EAD haben die Grundlage für eine bahnbrechende Zusammenarbeit gelegt, die regulatorische Compliance und Technik vereint, um beispiellose Effizienz und Exzellenz während des…

Read MoreIRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

European Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older Merck known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved…

Read MoreEuropean Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced…

Read MoreRoche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will celebrate a…

Read MoreBristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer

Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer  Roche announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a…

Read MoreRoche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer

AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION

AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Amgen and Horizon Therapeutics plc today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take…

Read MoreAMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION